Levofloxacin + OrnidazoleThird Party Manufacturing in India

Levofloxacin + Ornidazole is a synergistic fixed-dose combination that provides broad-spectrum coverage against both aerobic and anaerobic bacterial pathogens as well as protozoal infections. Levofloxacin, a broad-spectrum fluoroquinolone antibiotic, acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, two essential enzymes required for bacterial DNA replication, transcription, and repair. By stabilizing the cleaved DNA-enzyme complex, levofloxacin prevents the re-ligation of DNA strands, leading to the accumulation of double-stranded breaks and rapid bacterial cell death. Ornidazole is a 5-nitroimidazole derivative that works through a different and complementary mechanism: it undergoes reductive activation inside anaerobic microorganisms and susceptible protozoa. The reduced form of ornidazole generates cytotoxic intermediates and free radicals that damage microbial DNA, causing strand breakage and inhibition of nucleic acid synthesis. This reductive activation occurs specifically in the low-redox-potential environment of anaerobic bacteria and protozoa, providing selective toxicity against these organisms. Together, levofloxacin provides potent coverage against aerobic Gram-positive, Gram-negative, and atypical bacteria, while ornidazole extends the coverage to include obligate anaerobes such as Bacteroides fragilis, Clostridium species, and anaerobic cocci, as well as protozoal pathogens including Giardia lamblia, Entamoeba histolytica, and Trichomonas vaginalis.

Therapeutic Uses

Levofloxacin + Ornidazole is prescribed for the treatment of:

• Intra-Abdominal Infections: Provides comprehensive coverage for peritonitis, intra-abdominal abscesses, and biliary tract infections involving both aerobic and anaerobic pathogens.
• Pelvic Inflammatory Disease: Effectively treats polymicrobial pelvic infections including endometritis, salpingitis, and tubo-ovarian abscesses.
• Diabetic Foot Infections: Addresses the mixed aerobic-anaerobic microbiology commonly encountered in infected diabetic foot ulcers.
• Post-Surgical Wound Infections: Provides broad-spectrum prophylaxis and treatment for surgical site infections involving diverse microbial flora.
• Dental and Maxillofacial Infections: Treats odontogenic infections, periodontal abscesses, and orofacial infections with mixed aerobic-anaerobic etiology.
• Gastrointestinal Infections: Manages complicated diarrheal diseases including those caused by mixed enteric pathogens and protozoal co-infections.

Why Manufacturers Choose Levofloxacin + Ornidazole

Levofloxacin + Ornidazole is a cornerstone fixed-dose combination in surgical prophylaxis and the management of polymicrobial infections. The complementary antimicrobial spectrum — levofloxacin covering aerobes and ornidazole covering anaerobes and protozoa — makes this combination a practical and effective single-tablet solution for infections involving mixed microbial flora. It is widely prescribed by surgeons, gynecologists, gastroenterologists, and diabetologists, ensuring a broad and consistent prescriber base. The combination is included in hospital formularies across India and many developing countries for empiric therapy of intra-abdominal and pelvic infections. For pharmaceutical companies, this is a high-volume product with stable year-round demand and strong potential for both branded and generic markets. Manufacturing this combination at a WHO-GMP certified facility in India ensures cost-effective production, reliable quality, and regulatory compliance for domestic PCD pharma distribution as well as international export.

This makes Levofloxacin + Ornidazole one of the most widely prescribed antibiotic combinations for third party manufacturing in India, with significant demand from hospital supply chains, pharma franchise networks, and export markets across Asia and Africa.